Superpowers for Good

Superpowers for Good

SuperCrowd Voices

Preventing Cancer Before It Starts: Jonathan Cohen’s Bold Vision for Early Detection and Investor Impact

How 20/20 Biolabs Is Democratizing Cancer Screening with Affordable, At-Home Blood Tests—And Offering Investors A Rare Chance at Near-Term Liquidity

Devin D. Thorpe's avatar
Jonathan Cohen's avatar
Devin D. Thorpe and Jonathan Cohen
Aug 06, 2025
∙ Paid

We are pleased to share this SuperCrowd Voices from the Community post with you. SuperCrowd Voices posts represent the views of our guest authors, not The Super Crowd, Inc., a public benefit corporation. Manage the volume of emails you receive from us by clicking here. Interested in sharing your voice? Click here.

Join the SuperCrowd!

Despite staggering investments in cancer treatments, most patients still face limited benefits—especially when diagnosed late. Jonathan Cohen, founder and CEO of 20/20 Biolabs, believes that the true key to saving lives lies not in better treatments, but in earlier detection.

Jonathan Cohen, CEO of 2020 Biolabs

“I saw massive funding of and spending by biotech companies in developing treatments, but very little going to companies focused on early disease detection and prevention, which can be far more impactful,” Cohen says. “Unlike with infectious disease, the effectiveness of treatments for cancer and most chronic diseases is quite limited. Even the latest approved cancer dru…

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2026 Devin Thorpe · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for writing, podcasting, and media founders.